The effect of the apprise mandate on use of erythropoiesis-stimulating agents and transfusion rates in patients with ovarian cancer receiving chemotherapy

International Journal of Gynecological Cancer

Volumn 23, Issue 2, 2013, Pages 367-371

  Boone, Jonathan D ^a   Fauci, Janelle M ^a   Walters, Christy L ^a   Whitworth, Jenny M ^a   Bevis, Kerri S ^a   Alvarez, Ronald D ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Anemia; APPRISE; Erythropoiesis stimulating agent; Transfusion

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC METAL COMPLEX;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CHEMOTHERAPY INDUCED ANEMIA; CONTROLLED STUDY; COST CONTROL; ERYTHROCYTE TRANSFUSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVARY CARCINOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BLOOD TRANSFUSION; FEMALE; GUIDELINE ADHERENCE; HEMATINICS; HUMANS; MANDATORY PROGRAMS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATIENT SAFETY; RETROSPECTIVE STUDIES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84876260111     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e318276d9da     Document Type: Article

References (20)

1. BookmanMA, Brady MF,McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009;27:1419-1425.
2. Fujisaka Y, Sugiyama T, Saito H, et al. Randomised, phase III trial of epoetin-beta to treat chemotherapy-induced anaemia according to the EU regulation. Br J Cancer. 2011;105:1267-1272.
3. Chang J, Couture F, Young S, et al. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol. 2005;23: 2597-2605.
4. Hedley BD, Allan AL, Xenocostas A. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression. Clin Cancer Res. 2011;17:6373-6380.
5. Ross SD, Allen IE, Henry DH, et al. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: A systematic review of the literature. Clin Ther. 2006;28:801-831.
6. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol. 2005;23:5960-5972.
7. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet. 2003;362:1255-1260.
8. Temkin SM, Hellmann M, Serur E, et al. Erythropoietin administration during primary treatment for locally advanced cervical carcinoma is associated with poor response to radiation. Int J Gynecol Cancer. 2006;16:1855-1861.
9. Thomas G, Ali S, Hoebers FJ, et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol. 2008;108:317-325.
10. Rizzo JD, Brouwers M, Hurley P, et al. American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol. 2010;28:4996-5010.
11. Verbeke N, Beguin Y, Wildiers H, et al. High prevalence of anaemia and limited use of therapy in cancer patients: A Belgian survey (Anaemia Day 2008). Support Care Cancer. 2012;20:23-28.
12. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst. 1999;91:1616-1634.
13. Rodgers GM, A perspective on the evolution of management of cancer-and chemotherapy-induced anemia. J Natl Compr Canc Netw. 2012;10:434-437.
14. Harper P, Littlewood T. Anaemia of cancer: Impact on patient fatigue and long-term outcome. Oncology. 2005;69:2-7.
15. Caro JJ, Salas M, Ward A, et al. Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review. Cancer. 2001;91:2214-2221.
16. Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol. 2010;116:522-525.
17. Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med. 1999;340:409-417.
18. Hebert PC, Yetisir E, Martin C, et al. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? Crit Care Med. 2001;29:227-234.
19. Amgen's First Quarter 2012 Revenue Increased 9 Percent To $4.0 Billion And Adjusted Earnings Per Share (EPS) Increased 20 Percent To $1.61. April 24, 2012; Available at: Http://www.amgen.com/media/media-pr- detail.jsp? year=2012&releaseID=1686784. Accessed September 14, 2012.
20. Borg S, Glenngård AH, Osterborg A, et al. The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: A Markov model. Acta Oncol. 2008;47:1009-1017.